Rolls-Royce Holdings PLC (RR)
London Stock Exchange · UK · prices in GBX · close of 27 Oct 2026
Key indicators
| Last close | GBX 1,242.40 |
|---|---|
| 52-week range | 990.00 – 1,586.00 |
| Return, 1 month / 3 months | −16.1% / −11.8% |
| Return, 1 year / 3 years | +11.8% / +532.9% |
| Trend | Below its 200-day average |
| RSI (14) | 34 |
| Volatility (1 year) | 38.3% |
| Worst drawdown (1 year) | -25.6% |
| Average daily value traded | 25,204.59M GBX |
| Dividend yield | 0.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Rolls-Royce Holdings is a British engineering company based in London. It designs and builds aircraft engines for civil aviation and military customers, and supplies power systems and propulsion equipment for ships, submarines and industrial uses. The company also provides maintenance, repair and overhaul services that support its engines and equipment throughout their working lives. Its customers include airlines, armed forces and energy and marine operators around the world.
On this site Rolls-Royce Holdings PLC appears as a stock on the London Stock Exchange (UK), code RR, with prices in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 3 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Rolls-Royce Holdings PLC (RR) trades on the London Stock Exchange in UK. It last closed at GBX 1,242.40 on 27 October 2026.
Its price-based Market X-Ray is 55 out of 100 (a fair price profile), ranking 1,710 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 11.8% and over the last three months it fell 11.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 50 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -6.6% | ||
| From 52-week high | -20.9% | ||
| Momentum | 57 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -11.8% | ||
| 6-month return | 10.3% | ||
| 12-month return, skipping the last month | 33.4% | ||
| Stability (higher is calmer) | 51 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 38.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.6% | ||
| Liquidity | 100 · Strong | Trades actively. | |
| Average daily value traded | 25,204.59M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 9 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.9% | ||
| Years with dividends | 2 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −6.1% |
|---|---|
| 1 month | −16.1% |
| 3 months | −11.8% |
| 6 months | +10.3% |
| 1 year | +11.8% |
| 3 years | +532.9% |
| 5 years | +847.1% |
Signals
| 50-day / 200-day average | 1,433.98 / 1,330.57 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 52.81 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 6 Aug 2026 | GBP 0.0600 |
| 23 Apr 2026 | GBP 0.0500 |
| 7 Aug 2025 | GBP 0.0450 |
| 17 Apr 2025 | GBP 0.0600 |
| 24 Oct 2019 | GBP 0.0460 |
| 25 Apr 2019 | GBP 0.0710 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.